Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028287 · ClinicalTrials.gov registry record · Phase 4
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
A Phase 4 study of Diabetic Nephropathy and Nephrotic Syndrome, sponsored by Southeast Renal Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01028287 is a Phase 4 study of Diabetic Nephropathy and Nephrotic Syndrome that has completed, run by Southeast Renal Research Institute. The registered enrollment target is 15 participants, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01028287, a Phase 4 study of Diabetic Nephropathy and Nephrotic Syndrome, has completed, sponsored by Southeast Renal Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.
Conditions Studied
Interventions
- DRUG ACTH
Study Locations (1)
Tennessee
- Southeast Renal Research Institute - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028287
The ClinicalTrials.gov registry entry for NCT01028287 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The listed sponsor is Southeast Renal Research Institute, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which ACTH is the first listed.
NCT01028287 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01028287 about?
NCT01028287 is a clinical study titled "Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)". This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.
What is the current status of trial NCT01028287?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2009-05. Estimated completion is 2011-07.
What conditions does trial NCT01028287 study?
This clinical trial studies the following conditions: Diabetic Nephropathy, Nephrotic Syndrome.
What interventions are being tested in trial NCT01028287?
The interventions under investigation include: ACTH (DRUG).
Who is sponsoring clinical trial NCT01028287?
This trial is sponsored by Southeast Renal Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01028287 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
COMPLETED · Phase 2
-
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
COMPLETED · NA
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.